Biovie Inc. (BIVI) Stock Price & Analysis
Biovie Inc. (BIVI) fell 4.86% to USD 1.37 as of July 25, 2026 at 18:21 UTC, according to Nexqual real-time market data.
BIVI last closed at USD 1.44; the session ranged USD 1.34–1.49 on volume of 111,979 shares. Market capitalization is $10.33M, with a 52-week range of USD 1.06–7.75 (NCM). Source: Nexqual, July 25, 2026 at 18:21 UTC.
Key Statistics (as of July 25, 2026 at 18:21 UTC)
| Price | USD 1.37 |
|---|---|
| Change | ▼ 4.86% (down) |
| Previous Close | USD 1.44 |
| Open | USD 1.42 |
| Day Range | USD 1.34 – 1.49 |
| 52-Week Range | USD 1.06 – 7.75 |
| Volume | 111,979 shares |
| Market Cap | $10.33M |
| Exchange | NCM |
Technical Analysis (BIVI)
Nexqual's technical model rates BIVI "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 18:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.94 (neutral) |
| vs SMA50 | Below (USD 1.68) |
| MACD | -0.11 (negative) |
Analyst Ratings (BIVI)
Wall Street analysts rate BIVI "Strong Buy" based on 2 analysts, with a mean price target of USD 5.26 (range USD 5–5.51), per Nexqual as of July 25, 2026 at 18:21 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.26 |
| High Target | USD 5.51 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (BIVI)
| Next Earnings Date | 2026-08-24 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.98 vs est -0.79 ▼ miss |
| 2025-06-30 | USD -11.05 vs est -3.6 ▼ miss |
| 2025-03-31 | USD -1.5 vs est -3.2 ▲ beat |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
Financials & Fundamentals (BIVI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -106.43% |
| Debt / Equity | 1.9 |
| Current Ratio | 9.97 |
| Total Cash | $13.10M |
| Total Debt | $295,717 |
| Free Cash Flow | $-13.48M |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
Financial Health Score (BIVI)
Nexqual rates Biovie Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 18:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $13M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$21M |
| Efficiency | Critical — ROE -106%, ROA -61.0% |
Ownership (BIVI)
| Insider Ownership | +0.30% |
|---|---|
| Institutional Ownership | +13.94% |
| Shares Outstanding | 7.54M |
| Float | 7.50M |
| Short % of Float | +8.73% |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
Leadership (BIVI)
Biovie Inc. is led by Cuong Viet Do (age 59), President, CEO & Director, per Nexqual as of July 25, 2026 at 18:21 UTC.
| President, CEO & Director | Cuong Viet Do (age 59) |
|---|---|
| Senior Vice President of Operations | Clarence N. Ahlem (age 69) |
| Senior Vice President of Manufacturing & Development | Denise Smith |
| Senior Vice President of Alzheimer's Disease Program | Christopher L. Reading (age 77) |
Major Backers & Investors (BIVI)
Notable institutional backers of Biovie Inc. include Diametric Capital, Lp, Prelude Capital Management LLC, Morgan Stanley, according to Nexqual as of July 25, 2026 at 18:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Diametric Capital, Lp | 4.91% |
| Prelude Capital Management LLC | 1.22% |
| Morgan Stanley | 1% |
| Philadelphia Trust Company | 0.99% |
| Fidelity | 0.91% |
| Renaissance Technologies | 0.9% |
| Citadel | 0.6% |
| HRT Financial LP | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.72% |
| Geode Capital | 1.12% |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
From Biovie Inc.'s Latest SEC 10-K Filing (filed 2025-08-15)
Key Strengths & Strategy (as disclosed to the SEC)
- BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
- The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.
- It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| BCDA | BioCardia, Inc. | USD 0.85 | ▼ 6.59% |
| GRI | GRI Bio, Inc. | USD 1.45 | ▼ 2.03% |
| DRUG | Bright Minds Biosciences Inc. | USD 71.33 | ▼ 5.47% |
| TVGN | Tevogen Bio Holdings Inc. | USD 4.49 | ▲ 5.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 18:21 UTC. This page is informational and not investment advice.